Meclofenamic Acid

Summary

Meclofenamic Acid (CHEMBL509) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AG04) targeting PTGS1, PTGS2, and TRPM4; indicated across 3 conditions including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AG04 (+1 more)
• Targets: 3 (PTGS1, PTGS2, TRPM4)
• Indications: 3 conditions
• Clinical trials: 2
• Chemistry: 296.1 Da · C14H11Cl2NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL509
Name	Meclofenamic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4037
ChEBI	CHEBI:6710
ATC	M01AG04, M02AA18
Molecular formula	C14H11Cl2NO2
Molecular weight	296.1
InChIKey	SBDNJUWAMKYJOX-UHFFFAOYSA-N

SMILES: CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl

IUPAC name: 2-(2,6-dichloro-3-methylanilino)benzoic acid

ChEBI definition: An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, antirheumatic drug, antineoplastic agent, anticonvulsant, analgesic, antipyretic, EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor, EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor.

Also known as: Acide meclofenamique, Acido meclofenamico, CI-583, CL-583, INF 4668, INF-4668, Meclofenamate, Meclofenamic acid, NSC-95309, meclofenamic acid, meclotenamic acid, SID24424562

Parent form; salt/anhydrous children: CHEMBL876, CHEMBL1562610

Patent coverage: 11,176 distinct patent families (45,809 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 45,704 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGS1	COX-1	Inhibition	7.3	0%	P23219
PTGS2	COX-2	Inhibition	7.4	0%	P35354
TRPM4	TRPM4		5.47	0.5%	Q8TD43

Broader ChEMBL bioactivity targets: 26 (assay-derived). Sample: Nuclear receptor subfamily 4immunitygroup A member 1, Nuclear receptor ROR-gamma, Thromboxane A2 receptor, Menin/Histone-lysine N-methyltransferase MLL, Cyclooxygenase, Muscarinic acetylcholine receptor M1, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Alpha-ketoglutarate-dependent dioxygenase FTO, 3’,5’-cyclic-AMP phosphodiesterase 4A.

Bioactivity

ChEMBL activities: 35 potent at pChembl ≥ 5 of 49 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS2	7.96	IC50	11	nM	CHEMBL_ACT_7768500
PTGS1	7.85	AC50	14.2	nM	CHEMBL_ACT_25205169
PTGS1	7.77	AC50	17.1	nM	CHEMBL_ACT_25206102
PTGS2	7.4	IC50	40	nM	CHEMBL_ACT_859774
P05979	7.3	IC50	50	nM	CHEMBL_ACT_859773
P35355	7	IC50	100	nM	CHEMBL_ACT_320138
P35355	7	IC50	100	nM	CHEMBL_ACT_592653
P35355	7	IC50	100	nM	CHEMBL_ACT_694458
P35355	7	IC50	100	nM	CHEMBL_ACT_997263
Q05769	6.7	IC50	200	nM	CHEMBL_ACT_859776
PTGS1	6.69	IC50	203	nM	CHEMBL_ACT_7768498
PTGS1	6.66	IC50	220	nM	CHEMBL_ACT_12667375
P02692	6.59	Ki	256	nM	CHEMBL_ACT_2445259
P02692	6.42	Ki	379	nM	CHEMBL_ACT_2445232
Q05769	6.4	IC50	400	nM	CHEMBL_ACT_859777
TTR	6.32	Kd	480	nM	CHEMBL_ACT_15670989
TTR	6.3	IC50	504	nM	CHEMBL_ACT_28697909
AKR1C3	6.29	IC50	512	nM	CHEMBL_ACT_18758607
AKR1C3	6.27	IC50	540	nM	CHEMBL_ACT_12105591
AKR1C3	6.27	IC50	540	nM	CHEMBL_ACT_12667378
PTGS2	6.16	IC50	700	nM	CHEMBL_ACT_12667372
AKR1C1	6.13	IC50	740	nM	CHEMBL_ACT_18758622
RXRA	6.05	EC50	900	nM	CHEMBL_ACT_24986579
AKR1C1	5.5	IC50	3160	nM	CHEMBL_ACT_12105570
AKR1C1	5.5	IC50	3160	nM	CHEMBL_ACT_12667384
MAPK1	5.5	IC50	3144	nM	CHEMBL_ACT_7770641
NR4A1	5.33	EC50	4700	nM	CHEMBL_ACT_24986578
FTO	5.1	IC50	7940	nM	CHEMBL_ACT_24989147
FTO	5.1	IC50	8000	nM	CHEMBL_ACT_24989166
METTL3	5.1	IC50	8000	nM	CHEMBL_ACT_26037627

Target pathways

Aggregated over 3 target gene(s): PTGS1, PTGS2, TRPM4.

Top Reactome pathways

11 total, by targets touching each:

Pathway	Targets	Genes
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)	2	PTGS1, PTGS2
COX reactions	1	PTGS1
Synthesis of 15-eicosatetraenoic acid derivatives	1	PTGS2
TRP channels	1	TRPM4
Interleukin-10 signaling	1	PTGS2
Interleukin-4 and Interleukin-13 signaling	1	PTGS2
Biosynthesis of DHA-derived SPMs	1	PTGS2
Biosynthesis of EPA-derived SPMs	1	PTGS2
Biosynthesis of DPAn-3 SPMs	1	PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives	1	PTGS2
Sensory perception of sweet, bitter, and umami (glutamate) taste	1	TRPM4

Dominant GO biological processes

GO term	Targets
prostaglandin biosynthetic process	2
response to oxidative stress	2
regulation of blood pressure	2
cyclooxygenase pathway	2
regulation of cell population proliferation	2
long-chain fatty acid biosynthetic process	2
lipid metabolic process	2
fatty acid metabolic process	2
fatty acid biosynthetic process	2
prostaglandin metabolic process	2
prostanoid biosynthetic process	2
cellular oxidant detoxification	2
embryo implantation	1
response to nematode	1
response to selenium ion	1

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02930005	PHASE2	COMPLETED	Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders
NCT02429570	Not specified	ACTIVE_NOT_RECRUITING	Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

406 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
3,3’,4’,5-TETRACHLOROSALICYLANILIDE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ACEMETACIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ASPIRIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
BROMFENAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CAPSAICIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CAPTOPRIL	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CARPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CELECOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CIANIDANOL	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DEXIBUPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DEXKETOPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DICLOFENAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DOXORUBICIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ESFLURBIPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ETODOLAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ETORICOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
FLURBIPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
GLAFENINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
IBUPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
INDOMETHACIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
KETOPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
KETOROLAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
LEVODOPA	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
LOXOPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
LUMIRACOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
MEFENAMIC ACID	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
MELOXICAM	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
MOFEZOLAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
MONOBENZONE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
NAPROXEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
NIMESULIDE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
OMADACYCLINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
OXAPROZIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
PIROXICAM	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
PRIMAQUINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
RANITIDINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ROFECOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
SELINEXOR	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
SUPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
TEGASEROD	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
TELOTRISTAT	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
TOLMETIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
TROGLITAZONE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
VALDECOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
VORTIOXETINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CURCUMIN	ChEMBL	Phase 3	PTGS1, PTGS2
RESVERATROL	ChEMBL	Phase 3	PTGS1, PTGS2
CIMICOXIB	ChEMBL	Phase 2	PTGS1, PTGS2
DERACOXIB	ChEMBL	Phase 2	PTGS1, PTGS2
ENOFELAST	ChEMBL	Phase 2	PTGS1, PTGS2
FIROCOXIB	ChEMBL	Phase 2	PTGS1, PTGS2
FLUFENAMIC ACID	ChEMBL	Phase 2	PTGS1, PTGS2
LICOFELONE	ChEMBL	Phase 2	PTGS1, PTGS2
MAVACOXIB	ChEMBL	Phase 2	PTGS1, PTGS2
MIROPROFEN	ChEMBL	Phase 2	PTGS1, PTGS2
NIFLUMIC ACID	ChEMBL	Phase 2	PTGS1, PTGS2
PHENOTHIAZINE	ChEMBL	Phase 2	PTGS1, PTGS2
PIRMAGREL	ChEMBL	Phase 2	PTGS1, PTGS2